LuciGefi — Gefitinib 250 mg, 30 pcs, Lucius

LuciGefi — Gefitinib Tablets 250 mg, 30 Tablets

Product code: 496

4247₴ 4604₴ -8% On order · from 10 days

Analogues

Geftinat LuciGefi
1
Active ingredient
Dosage
250 mg
Dosage form Tablets
Tablets per pack 30

LuciGefi is a targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of locally advanced or metastatic non-small cell lung cancer. The active pharmaceutical ingredient is gefitinib at a strength of 250 mg supplied as film-coated oral tablets (Gefitinib Tablets 250 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR - HER1) tyrosine kinase. It blocks intracellular signaling pathways essential for the growth, survival, and proliferation of tumor cells expressing mutant EGFR. Gefitinib is most effective in patients harboring activating EGFR mutations (such as exon 19 deletions or exon 21 L858R point mutations). Gefitinib significantly delays disease progression, improves quality of life, and demonstrates robust antitumor activity with a favorable tolerability profile compared to conventional chemotherapy.

Supplied in a package containing 30 tablets of 250 mg (a full 1-month treatment course). Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciGefi 250 mg:

  • ✅ Selective Targeted Action: Selective inhibition of tumor cell EGFR kinase with minimal normal tissue toxicity.
  • ✅ Proven Efficacy in EGFR Mutations: High therapeutic activity in NSCLC patients harboring activating EGFR mutations.
  • ✅ Convenient Oral Regimen: Taken orally once daily regardless of food intake.
  • ✅ Enhanced Quality of Life: Lower incidence of severe systemic adverse effects compared to traditional cytotoxic chemotherapy.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Iressa).

LuciGefi is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Gefitinib — 250 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, sodium lauryl sulfate. Coating: hypromellose, macrogol, titanium dioxide, colorants.

Packaging and Presentation: Film-coated tablets, 250 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciGefi (Gefitinib Tablets 250 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Gefitinib is a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. EGFR is expressed on the cell surface of both normal and tumor cells. Gefitinib competitively inhibits ATP binding to the EGFR kinase domain, preventing receptor autophosphorylation and blocking downstream signaling cascades, resulting in cell cycle arrest and tumor cell apoptosis.

Pharmacokinetics:

  • Absorption: Following oral ingestion, absorption is relatively slow. Peak plasma concentration (Tmax) is achieved within 3 to 7 hours. Food intake does not clinically affect absorption.
  • Distribution: Plasma protein binding (albumin and alpha-1-acid glycoprotein) is approximately 90%. Large volume of distribution (mean 1400 L).
  • Metabolism: Extensively metabolized in the liver predominantly via cytochrome P450 enzymes (mainly CYP3A4 and CYP2D6).
  • Elimination: Excreted predominantly via feces (approx. 86%) and renally (<4% as unchanged drug). Terminal elimination half-life (T1/2) averages approximately 41 hours.

LuciGefi is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring activating EGFR mutations (as first-line therapy or following disease progression on prior chemotherapy).

LuciGefi is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard daily dose is 250 mg (1 tablet) once daily.

Administration Guidelines:
Tablets can be taken with or without food, swallowed with water. Tablets must be swallowed whole; do not break, crush, or dissolve. If swallowing whole is difficult, tablets may be dispersed in half a glass of non-carbonated drinking water (stir until dispersed without crushing and drink immediately, rinsing the glass with water).

Administration of LuciGefi is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to gefitinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.

Gefitinib is metabolized by hepatic cytochrome P450 enzymes (predominantly CYP3A4):

  • Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, barbiturates, St. John's Wort): Significantly decrease gefitinib plasma concentrations and reduce efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): Increase gefitinib blood concentrations and toxicity risks.
  • Gastric pH-Altering Agents (proton pump inhibitors, antacids): May reduce gefitinib bioavailability and blood concentrations. Avoid concurrent administration of omeprazole or similar agents.

Pregnancy:
LuciGefi is contraindicated during pregnancy. Gefitinib may cause fetal harm when administered to pregnant women. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 2 weeks following the final dose.

Lactation:
Excretion of gefitinib into human breast milk is unknown. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions (Very Common): Acneiform rash, dermatitis, dry skin, pruritus, skin fissures, nail disorders (paronychia).
  • Gastrointestinal Tract (Very Common): Diarrhea, nausea, vomiting, stomatitis, decreased appetite.
  • Hepatic Abnormalities: Asymptomatic elevations in liver transaminases (ALT, AST), bilirubin. Regular liver function monitoring required.
  • Ocular Disorders: Conjunctivitis, blepharitis, dry eye, corneal erosion.
  • Rare but Severe Effects: Interstitial lung disease (pneumonitis), which can be severe and requires immediate drug discontinuation upon onset of cough or dyspnea.

Symptoms:
Specific acute overdose symptoms of gefitinib are unestablished. Administration of higher doses has resulted in increased frequency and severity of adverse reactions (primarily skin rashes and diarrhea).

Treatment:
No specific antidote exists. Supportive and symptomatic care should be initiated in case of overdose.

Storage Requirements for LuciGefi 250 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciGefi 250 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Gefitinib Tablets 250 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00